In Vitro: Bizelesin (0-5 μM, 4 h) can cause DNA-specific damage by targeting the AT-rich DNA domain in human cancer cell CEM cells, thereby causing damage to cancer cells, and has potential cancer therapeutic potential. Bizelesin (0-500 nM) causes a 50% inhibition of DNA synthesis at a concentration of 10 nM, compared to a 50% inhibition of RNA synthesis at a concentration of 160 nM, at concentrations as high as 200 nM no inhibition of protein synthesis is observed in BSC-1 cells.